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Abstract: 
The development of a mammalian brain is a complex and long-lasting 
process. Not surprisingly, preterm birth is the leading cause of death in 
newborns and children. Advances in perinatal care reduced mortality but 
morbidity still represents a major burden. New therapeutic approaches are 
thus desperately needed. Given that mesenchymal stem/stromal cells 
(MSCs) emerged as a promising candidate for cell therapy, we transplanted 
MSCs derived from the Wharton`s jelly (WJ-MSCs) to reduce the burden of 
immature brain injury in a murine animal model. WJ-MSCs transplantation 
resulted in protective activity characterized by reduced myelin loss and 
astroglial activation. WJ-MSCs improved locomotor behavior as well. To 
address the underlying mechanisms we tested the key regulators of 
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responses to DNA damaging agents such as cyclic AMP dependent protein 
kinase / calcium-dependent protein kinase (PKA/PKC), cyclin-dependent 
kinase (CDK), ataxia-telangiectasia-mutated/ATM- and Rad3-related 
(ATM/ATR) substrates, Protein kinase B (Akt), and 14-3-3 binding protein 
partners. We characterized WJ-MSCs using a specific profiler PCR array. We 
provide evidence that WJ-MSCs target pivotal regulators of the cell fate 
such as CDK/14-3-3/Akt signaling. We identified leukemia inhibitory factor 
as potential candidate of WJ-MSCs` induced modifications as well. We 
hypothesize that WJ-MSCs may exert adaptive responses depending on the 
type of injury they are facing, making them prominent candidates for cell 
therapy in perinatal injuries. 
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Abstract 
The development of a mammalian brain is a complex and long-lasting process. Not 
surprisingly, preterm birth is the leading cause of death in newborns and children. 
Advances in perinatal care reduced mortality but morbidity still represents a major 
burden. New therapeutic approaches are thus desperately needed. Given that 
mesenchymal stem/stromal cells (MSCs) emerged as a promising candidate for cell 
therapy, we transplanted MSCs derived from the Wharton`s jelly (WJ-MSCs) to 
reduce the burden of immature brain injury in a murine animal model. WJ-MSCs 
transplantation resulted in protective activity characterized by reduced myelin loss 
and astroglial activation. WJ-MSCs improved locomotor behavior as well. To address 
the underlying mechanisms we tested the key regulators of responses to DNA 
damaging agents such as cyclic AMP dependent protein kinase / calcium-dependent 
protein kinase (PKA/PKC), cyclin-dependent kinase (CDK), ataxia-telangiectasia-
mutated/ATM- and Rad3-related (ATM/ATR) substrates, Protein kinase B (Akt), and 
14-3-3 binding protein partners. We characterized WJ-MSCs using a specific profiler 
PCR array. We provide evidence that WJ-MSCs target pivotal regulators of the cell 
fate such as CDK/14-3-3/Akt signaling. We identified leukemia inhibitory factor as 
potential candidate of WJ-MSCs` induced modifications as well. We hypothesize that 
WJ-MSCs may exert adaptive responses depending on the type of injury they are 
facing, making them prominent candidates for cell therapy in perinatal injuries. 
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Introduction 
Preterm birth is a complex multifactorial syndrome and together with intrapartum-
related complications the leading cause of death in newborns and children [1,2]. This 
is especially evident in very low gestational age infants (< 32 weeks gestation) where 
advances in perinatal care reduced mortality but morbidity still represents a major 
burden [3,4]. The magnitude of this medical and socioeconomic burden is enormous. 
Depending on the degree of prematurity, up to 20% of infants will develop spastic 
cerebral palsy (CP) and up to 50% demonstrate cognitive, behavioral, motor and 
sensory deficits, or higher incidence of psychiatric disorders [5][6]. 
In immature infants at risk, no individual protective agent has proven safe and 
effective so far [7-9]. Magnesium sulfate reduces the incidence of CP in the preterm 
population, but identification of pregnant mothers with anticipated preterm labor is 
difficult [10]. New therapeutic approaches are thus desperately needed. In recent 
years, mesenchymal stem/stromal cells (MSCs) emerged as a promising candidate 
for cell therapy targeted against perinatal brain injury [11]. MSCs isolated from the 
stroma of the umbilical cord (Wharton`s jelly; WJ-MSCs) [12,13] are of special 
interest as they are easy available around the time of birth, an autologous source, 
and pose no ethical concerns [14,15]. In addition, WJ-MSCs possess a low 
immunogenic capacity and a multipotent differentiation potential [13]. MSCs were 
shown to modulate innate and adaptive immune responses, to have anti-apoptotic 
effects, to decrease inflammation, and to enhance tissue repair, mostly through the 
release of paracrine factors [16,17]. 
The development of a mammalian brain is a complex and long-lasting process which 
follows specific time- and space-dependent sequences with interactions of various 
cell types. One of the common denominators is the dynamic equilibrium of cellular 
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proliferation/differentiation and apoptosis/necrosis which is especially evident in 
responses to aggressors in the immature brain. Not surprisingly, both inflammation 
and hypoxia-ischemia result in the predilection for white matter injury due to 
aggressors ranging from oxidative stress to excitotoxicity [14,18]. Generally, in 
response to DNA damage, the cell cycle checkpoints’ activation at the G1/S and G2/M 
transitions may stop cell cycle progression to repair the damaged genetic material.  In 
case of irreparable DNA damage, the cells will induce apoptosis [19]. The key 
regulators of responses to DNA damaging agents are cyclic AMP dependent protein 
kinase / calcium-dependent protein kinase (PKA/PKC), cyclin-dependent kinase 
(CDK), ataxia-telangiectasia-mutated/ATM- and Rad3-related (ATM/ATR) substrates, 
Protein kinase B (Akt), and 14-3-3 binding protein partners [20-26]. For example, 
activation of PKA/PKC signaling results in the protection of an immature brain [21] 
and CDK inhibition proved to be protective in stroke [19]. Activation of ATM/ATR 
signaling results in neuronal apoptosis [26] and Akt signaling is a well-defined pro-
survival pathway [20]. Further, 14-3-3 proteins have been shown to be 
neuroprotective in a variety of neurological disorders [27,28]. 14-3-3 proteins 
represent a homologous family which bind their substrates through an amphipatic 
binding cleft leading to a variety of effects including stress response, apoptosis, 
transcriptional regulation, cell cycle regulation [24]. Together, targeting these cell fate 
pathways represent a potential neuroprotective strategy in an immature brain. 
In this report, we show the effect of WJ-MSCs in a clinically relevant murine model of 
immature brain injury. WJ-MSCs transplantation exerts protective effects at both 
histological and behavioral level. We provide evidence that WJ-MSCs target pivotal 
regulators of the cell fate as well. Our result support the notion of WJ-MSCs as an 
attractive cell graft in immature infants at risk. 
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Methods 
All procedures have been approved by the local institutional review board (Ethics 
Committee and Veterinary Department of the Canton of Berne, Switzerland). We 
obtained a written informed consent from all umbilical cord donors. 
Cell graft: Wharton’s jelly-derived MSCs 
Human WJ-MSCs were isolated and characterized as previously published [12,29]. 
Briefly, umbilical cords were chopped, digested in 270 U/mL collagenase II 
(Worthington Biochemical Corporation, Lakewood, NJ, USA) at 37°C/5% CO2, and 
cultured in DMEM/F12 10% containing fetal calf serum (FCS), 2 mmol/L glutamax, 
and 100 units/mL penicillin / 100 mg/mL streptomycin / 250 ng/mL amphotericin B 
(Thermo Fisher Scientific, Waltham, MA). The WJ-MSC were characterized by 
fluorescence-activated cell sorting (FACS) as follows: Antibody stainings were 
performed for 30 minutes at 4°C. Antibodies were diluted in 1x phosphate-buffered 
saline (PBS), 1% fetal calf serum (FCS). FITC-conjugated mouse monoclonal 
antibodies against the following markers were used: human CD105 (AbD 
Serotec,  Oxford, UK), human CD90 (Acris Antibodies, San Diego, CA), human CD45 
(BD Pharmingen, Franklin Lakes, NJ), human CD34 (BD Pharmingen), human CD14 
(Millipore, Billerica, MA) and human HLA-DR (BD Pharmingen). The unconjugated 
mouse monoclonal antibodies against human CD73 (BD Pharmingen) and CD19 
(Millipore) were detected with Alexa-Fluor 594-conjugated anti-mouse IgG antibody 
(Thermo Fisher Scientific). The positive fraction was determined using unstained 
cells control. After staining, cells were fixed in 1% paraformaldehyde (PFA) and 
10’000 events were acquired on a LSR II flow cytometer (BD Biosciences, Franklin 
Lakes, NJ). Analysis was done using the FlowJo software (Tree Star, Inc., Ashland, 
OR). 
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Animal Model: Perinatal Brain Injury 
We induced immature brain injury as we had previously described [21,30]. Briefly, 
neonatal Wistar rats were randomly divided into 3 groups (Sham, Injury, and 
Injury+WJ-MSCs; n=19). The Injury and Injury+WJ-MSCs groups received 
Lipopolysaccharides (LPS: 0.1mg/kg BW, i.p.) at postnatal day 3 (P3). On the 
following day, the left common carotid artery was double-ligated using a 
stereomicroscope and animals were subjected to mild hypoxia (8% O2/ 92% N2; 40 
minutes). The Sham Group (n=6) consisted of uninjured animals (0.9% NaCl instead 
of LPS i.p., exposure of carotid artery without ligation, no hypoxia and no further 
treatment). The Injury+WJ-MSCs Group (n=7) received a single cell graft 
transplantation into the lateral ventricle. We transplanted 250‘000 of WJ-MSCs into 
the left ventricle at postnatal day 11 as published previously [29]. Briefly, 
anesthetized animals were fixed on a block heated to 37°C in a small animal 
stereotaxic frame (David Kopf Instruments, Tujunga, CA). We injected a volume of 
5µL over approx. 6 min into the lateral ventricle using a Lab Animal Studies Injector 
(Hamilton, Bonaduz, Switzerland) with a 32 gauge needle. The needle was left in 
place for 2 min after injection and then withdrawn slowly. The Injury Group (n=6) 
received no WJ-MSCs treatment but the needle was placed into the ventricle without 
vehicle injection. 
Functional tests 
To assess the functional outcome after brain injury, we performed a walking pattern 
analysis [31]. Briefly, rats with stained hind paws were placed on an inclining 
gangway and walked up the gangway and into a dark box. Paper strips with 
footprints were scanned and stride length (the distance between steps of the same 
side) and toe distance (distance between the 1st and 5th toe) were measured for the 
left and right hind paw.  
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Perioperative Care of the Animals 
See Supplementary Information for details.  
Tissue Harvesting and Immunohistochemistry 
We performed brain harvesting on P39 (n=19; Fig. 1C). Briefly, we deeply 
anesthetized animals with sodium thiopental (100mg/kg body weight i.p., Inresa, 
Freiburg, Germany) and sacrificed by cardiac perfusion with PBS followed by 
formaldehyde (4%; Merck, Darmstadt, Germany). Animals were decapitated and we 
removed brains surgically and fixed in formaldehyde solution (4%) for 2-4 hours at 
room temperature (RT) followed by 4°C for a total time of 24-48 hours. Fixed brains 
were embedded in paraffin and sectioned into 7µm slices. 
For further details on tissue immunohistochemistry see Supplementary Information 
Tissue Harvesting and Western Blots 
To dissect WJ-MSCs protective mechanisms in the brain tissue (n=3 each group), we 
induced brain injury as described above with following changes (see Supplementary 
Information for details). Whole brain lysates for kinome profiling were isolated 
following a protocol developed by Cell Signaling Technology (Danvers, MA). Briefly, 
tissue or cells were homogenized (lysate was passed through 20G needles 10 times 
for each sample) in lysis buffer (20mM HEPES pH 8.0, 9M urea, 1mM sodium 
orthovanadate, 2.5mM sodium pyrophosphate, 1mM β-glycerophosphate), sonicated, 
and cleared by centrifugation. Protein concentration was measured using the 
Bradford assay and a total of 30 µg protein was loaded for each lane. Protein bands 
on Western blots were quantified using Image J using β-actin as control [32]. The 
following antibodies were used: phospho-PKA/PKC substrate, No 9624, 6967; 
phospho-CDK/tXR substrate, No 9477, 8139; phospho-ATM/ATR substrate, No 
9607, 6966; phospho-Akt substrate, No 9614, 10001; 14-3-3 Binding partners, No 
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9442; all from Cell Signaling Technology. For LIF detection we used antibody from 
Millipore (No: MAB4306, CA, USA).  
Induction of WJ-MSC into neural progenitor cells and gene Array 
To further characterize WJ-MSCs, we differentiated them at cell culture passage 5 
(WJ-MSC derived from preterm birth: gestational week < 37 weeks) into 
neurospher s [33]. Briefly, after an immediate differentiation step in DMEM/F12 
medium containing 1 x N2 supplement (Life Technologies), 10 ng/ml epidermal 
growth factor (EGF; R&D Systems, Minneapolis, Minnesota), 2 mmol/l glutamax, and 
100 units/mL penicillin/100 mg/ml streptomycin/250 ng/ml amphotericin B, the cells 
were cultured in suspension in neurobasal medium (Life Technologies) containing 1 x 
B27 supplement (Life Technologies), 20 ng/ml EGF, 20 ng/ml basic fetal growth 
factor (bFGF; Peprotech, Rocky Hill, New Jersey), 2 mmol/l glutamax, and 100 
units/ml penicillin/100 mg/ml streptomycin/250 ng/ml amphotericin B to induce 
neurosphere-like bodies. We extracted RNA and proteins from cell culture (WJ-MSC 
at passage 5 and neurospheres) using the QIAshredder and the RNAeasy Plus 
MiniKit from Qiagen (Hilden, Germany: according to the protocol) and proteins as 
previously performed [33]. RNA concentration was measured by Nanodrop 
spectrometry (Thermo Scientific, Wilmington, Delaware). Up to 5 µg of RNA were 
reverse transcribed using the RT2 First Strand cDNA (Qiagen). The Neurotrophins 
and Receptors RT2 profiler PCR array (Qiagen) was used to measure the 
transcription of genes related to neurotrophic signaling. The plates were supplied pre-
coated with forward and reverse primers. For one 96-well plate, 102 µl cDNA was 
mixed with 1350 µl 2x RT2 SYBR Green ROX qPCR mastermix and 1248 µl 
nuclease-free water. 25 µl of the PCR component cocktail were pipetted into each 
well. The following cycling program was used to run the PCR on a 7300 Real Time 
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PCR System (Life Technologies): 10 min at 95°C, followed by 40 cycles of 15 s at 
95°C and 1 min at 60°C.  
Quantitative Assessment of the Brain  
We performed quantitative assessments in the region of interest (ROI) defined as 
deep cerebral cortex (cortical layers V and VI in Figure 108 according to a neonatal 
rat brain atlas) [34] and in each hemisphere independently. Notably, ROI is the 
expected area of injury and hypoxia-ischemia was reported to cause distinctive 
neuropathological alterations in these regions of the parieto-occipital cortex and white 
matter tracts [21,30,35]. We acquired images using a BX51 microscope (Olympus, 
Tokyo, Japan) with a 40× objective and equipped with a digital camera. An 
independent observer acquired six consecutive ROI sections visual field by visual 
field without overlapping per hemisphere and animal for each specific 
immunostaining blinded to the experimental conditions. To asses myelin loss (MBP 
immunostaining) and astrogliosis (GFAP immunostaining), we measured the 
percentage of positive MBP and GFAP staining (area) in the ROI in each hemisphere 
as described previously [36,37]. We determined the difference between contralateral 
(undamaged) and ipsilateral (damaged) hemispheres using Image J [32]. 
Data analysis 
We avoided variability resulting from tissue handling and staining, and inter-animal 
developmental variations by using a ratio of left (ipsilateral to carotid occlusion) to 
right hemisphere [38,39]. Data are represented as mean ± SEM. Single comparisons 
to control were made using two-tailed Student’s t-test or Mann-Whitney test. We used 
one-way repeated measures ANOVA followed by Bonferroni's Multiple Comparison 
Test for multigroup design. P < 0.05 was considered to be statistically significant. No 
statistically significant differences were detected between the contralateral (uninjured 
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hemispheres) in all groups. For gene array data analysis was performed by the delta-
delta Ct method using the company’s software provided on their webpage and 
expressed as fold change in WJ-MSC derived from preterm delivery (n=3) relative to 
neurosphers from preterm birth (n=3). Data handling and statistical processing was 
performed using Microsoft Excel and GraphPad Prism Software. 
Results 
WJ-MSCs as a cell graft 
We decided to use WJ-MSCs as a cell transplant as they are considered an attractive 
source for perinatal transplantation [11,40]. The isolated WJ-MSCs were adherent to 
plastic and displayed a fibroblast-like phenotype (Fig. 1A) [33]. Further, after five 
passages, we detected characteristic MSCs cell surface markers (Fig. 1B) [41]. To 
test our hypothesis that our cell graft protects the immature brain, we used a well-
established murine model (Fig. 1C) [21,30]. We evaluated the migration of WJ-MSCs 
by staining for HLA-ABC-positive cells at P39. In line with previous studies, we 
detected only few positive cells (Fig. 1D) [42] in the cortex cerebri, hippocampus and 
striatum [29]. We did not detect any signs of differentiation in line with previous 
studies [43,44]. 
WJ-MSCs protect against immature brain injury 
To test the effectiveness of WJ-MSCs treatment in immature brain injury, we 
evaluated loco-motor behavior first (Fig.2A). In line with previous reports, we 
detected abnormal walking behavior after the brain insult, namely a significant 
change of step length and toe distance (Fig.2A; compare left to right hind paws’ step 
length and toe distance of Injury vs. Sham groups) [31]. WJ-MSCs transplantation 
resulted in the alleviation of spastic paresis and restored motor symmetry (Fig.2A; 
compare left to right hind paws’ step length and toe distance of Injury vs. Injury+WJ-
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MSCs groups). To determine the underlying pathophysiology, we focused on the 
motor cortex with emphasis on the characteristic deep cortical layers as these 
regions are altered as a consequence of immature brain injury [35,45] and 
associated with impaired loco-motor behavior [31].  
We evaluated the number of NeuN-positive cells (mature neurons) in deep cortical 
layers first, as injury and hypoxia-ischemia at this time point were reported to cause 
distinctive neuropathological alterations in these regions [21,30,35]. We did not 
detect neuronal loss (Fig.2B; compare ipsilateral injured to contralateral intact 
hemisphere Sham vs. Injury) [36,46]. However, we need to consider that in contrast 
to our previous studies [21,30], we induced a “mild” injury (hypoxia reduced to 40 
minutes). Additionally, the most common neuropathology in premature infants is not 
focal necrosis but diffuse non-cystic alterations [14,18]. As these alterations evolve 
over time to glial scars characterized by microgliosis and astrogliosis, we tested them 
next. 
Given that the hallmark of immature brain injury is the degeneration of immature 
oligodendrocytes and a resulting loss of mature oligodendrocyte markers like myelin 
basic protein (MBP), we tested for myelin loss [47-49]. We detected a significant 
myelin loss after injury (Fig.2C: compare ipsilateral injured to contralateral intact 
hemisphere Injury vs. Sham groups) [50,51]. Importantly, transplantation of WJ-
MSCs resulted in an amelioration of the induced MBP loss (Fig. 2C: compare 
ipsilateral to contralateral hemisphere Injury vs. Injury+WJ-MSCs groups). Besides 
demyelination, glial activation is another prominent event after immature brain injury, 
so we tested astroglial activation next [35,52]. We detected increased astroglial 
activation in the cortex following injury (Fig. 2D: compare ipsilateral to contralateral 
hemisphere Injury vs. Sham groups). In line with myelin protection, WJ-MSCs 
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reduced astroglial activation significantly (Fig. 2D: compare ipsilateral to contralateral 
hemisphere Injury vs Injury+WJ-MSCs groups). Collectively, our results support the 
notion that WJ-MSCs attenuate the induced injury in an immature brain characterized 
by cortical changes such as myelin loss and astroglial activation, which underlie the 
resulting loco-motor behavioral changes [36,46]. 
WJ-MSCs modulate PKA/PKC, CDK, Akt signaling, and 14-3-3 binding in the 
immature brain 
Our results indicate that transplantation of WJ-MSCs protects the immature brain 
against injury (Fig. 2 compare Injury vs. Injury+WJ-MSCs groups). However, the 
underlying mechanisms remain unclear. To investigate these mechanisms, we chose 
a global screening approach to detect key regulators of responses to DNA damage 
and probed the brain tissues against well-characterized motif specific antibodies [21]. 
These antibodies detect specific post-translational modifications in the context of 
specific binding motif or substrate. Thus, we assess not a single target but rather 
have a global overview.  
We tested PKA/PKC first as they are important signaling molecules in a variety of 
cellular functions including cellular response to hypoxia-ischemia or oxidative stress 
[21,53,54]. In line with previous reports, injury to an immature brain resulted in the 
activation of PKA/PKC signaling (Fig.3A) [21]. Surprisingly, WJ-MSCs did not further 
activate PKA/PKC but rather decreased it significantly (Fig.3A).  
In search for other potential mechanisms and given the emerging importance of CDK 
inhibitors in oncology and their potential use in stroke, we tested for CDK substrates 
[19]. In stroke, ischemic brain injury results in an activation of CDK signaling and 
CDK inhibition is protective [19]. Immature brain injury did not affect CDK signaling 
and we detected CDK activation after cell graft transplantation (Fig.3B). To further 
elucidate the graft response, we tested ATM/ATR signaling as ATM is upstream of 
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CDK in cell cycle arrest [26,55,56]. We did not detect any significant changes 
(Fig.3C), which suggests that the observed cell graft-mediated CDK activation is 
ATM/ATR-independent. Next, we tested phosphorylated Akt substrates and 14-3-3 
binding partners as they modulate the cell cycle progression, are crucial CDK 
partners, and reported neuroprotective targets [20,24,57,58]. In line with CDK 
activation, WJ-MSCs treatment increased phosphorylation of Akt substrates and 14-
3-3 binding partners (Fig.3D and E). Together, our results provide evidence that WJ-
MSCs protect the immature brain and modulate cell fate signaling pathways (Fig. 3F) 
involved in brain protection.   
WJ-MSCs express neurotrophic factors  
Given the modifications after transplantation of WJ-MSCs (Fig. 3) and WJ-MSCs` 
protective effects (Fig. 2), we aimed to further characterize the cell graft using a gene 
array [33]. We decided to compare WJ-MSCs to differentiated neurospheres derived 
from WJ-MSCs as WJ-MSCs have a “multi-differentiated” potential. It is the potential 
to express factors from other tissues before any differentiation. Thus, we aimed to 
detect changes unique to the relatively heterogeneous cell population of WJ-MSCs 
[33]. In line with this potential, we detected increased expression of neurotrophic 
factors and receptors involved in brain development and response to injury such 
nerve growth factor receptor (NGFR) and GDNF family receptor alpha 3 (GFRA3) 
[59,60] (all genes summarized in Table 1). We detected increased expression of 
Prostaglandin E receptor 2 (PTGER2) which in stroke protects against oxidative 
stress in a PKA dependent manner [61]. Interestingly, we detected increased 
expression of leukemia inhibitory factor (LIF) as well. LIF is an important factor 
contributing to a variety of cellular processes such as neuronal development, 
astroglial responses to injury, and oligodendrocyte survival [62-65]. Importantly, LIF 
exerts its biological effects partially through Akt, CDK, and 14-3-3 signaling pathways 
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[63,66,67] which makes it a potential candidate of the WJ-MSCs` induced 
modifications (Fig. 3). We confirmed increased LIF expression in WJ-MSCs on 
protein level as well (Fig. 3G). 
Together, we hypothesize that WJ-MSCs may exert adaptive responses depending 
on the type of injury they are facing, making them prominent candidates for cell 
therapy in perinatal injuries. 
Discussion: 
This report documents that WJ-MSCs transplantation exerts protective effects 
against immature brain injury. Using a clinically relevant model, we demonstrate that 
our cell graft (Fig. 1) is able to ameliorate myelination loss and astroglial activation 
while preserving proper functional behavior (Fig.2). Most importantly, we are the first 
to report that WJ-MSCs target crucial signaling pathways involved in cell cycle 
regulation and apoptosis (Fig. 3F), while expressing growth and differentiation factors 
(Tab. 1). Together, we provide evidence that WJ-MSCs are potential candidates for 
treatment of immature infants at risk. 
MSCs and MSC-derived therapies emerged in the last decades as a potential 
paradigm-shift for complex multifactorial diseases such as immature brain injuries 
[68]. As the preterm infant faces multiple risk factors including inflammation/infection, 
ischemia/reperfusion, and deprivation of placental protective factors, an optimal 
therapeutic should target the injuries globally (several organs) and locally (response 
to signals of local injury) [11]. In our study, WJ-MSCs protect the immature brain and 
modulate different signaling pathways. This is particularly interesting as it fuels the 
constant debate whether MSCs or MSC-derived products such as conditioned media 
or exosomes are the optimal choice for treating perinatal injuries. We hypothesize 
that the WJ-MSCs’ ability to locally respond to signals after injury is an advantage, 
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but the direct comparison between WJ-MSCs and their products in perinatal injury 
models needs to be assessed in future studies [68]. From a clinical point of view, 
precautions and long-term adverse consequences need to be considered as in the 
immune compromised developing preterm infant, stem cells have the theoretical 
potential to enhance tumor growth [69].  
Another important consideration is the route of stem cell transplantation and the 
animal model. We tested WJ-MSCs in a well-established model of immature brain 
injury [21,30,36]. We induced injury at P3/4 a time point which corresponds to a high-
risk period of human preterm infants with immature oligodendrocyte development 
peak [46]. Expectantly we detected myelin loss with motor and sensory deficits (Fig. 
2A and C) [36,46]. However, preterm survivors demonstrate cognitive and behavioral 
deficits with higher incidence of psychiatric disorders as well [5,6]. Thus, studies 
identifying MSC`s effects after P3/4 injury are needed. Especially as injury at P4 may 
result in postnatal maturation and affective disorders [70]. Multiple transplantation 
routes for brain injuries including intracerebral, intraperitoneal, intranasal, or 
intravenous were introduced [69]. Indeed, we chose an invasive route but a 
straightforward approach, as we aimed to determine direct effects on the immature 
brain. Given that the graft preparation and optimal administration route remains 
unclear [71], further non-invasive studies are warrant but beyond the scope of this 
manuscript [29,72]. From a clinical point of view evaluation of the optimal cell 
transplant is obligatory. Although we did not detect morphological changes of the cell 
graft over time (Fig. 1D), longitudinal assessment of the cell graft fate are still 
needed, especially as we used a xenograft. Additionally, preparation of the graft prior 
to transplantation such as removal of fetal bovine serum needs to be assessed prior 
to clinical utilization. 
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Numerous studies postulate that MSCs protective effects after perinatal injury are 
based on paracrine effects and immunomodulation [11]. In contrast to upcoming 
novel immunomodulation therapies such as PreImplantation Factor, WJ-MSCs did 
not impact PKA/PKC signaling after injury [21]. Given the diverse modes of action, a 
combined therapeutic approach may provide superior protection due to synergistic 
effects. Another surprising finding is that WJ-MSCs activate CDK signaling in the 
brain while CDK inhibition protects neurons in stroke or traumatic brain injury [19,73]. 
However, when considering this opposite effects, the distinct pathophysiology of an 
immature brain and time point of the evaluation need to be accounted for. For 
example, in an immature brain, cell proliferation and differentiation, especially in the 
case of oligodendrocyte progenitors, depend on proper CDK activity [55,74]. Further, 
in stroke CDK activation was detected up to 24 hours of reperfusion injury only [19]. 
Given that CDK modulation was not detected after injury (Fig. 3B: compare Injury vs 
Sham) and neuroprotective Inhibition of CDKs is present in adult animals only [75], 
suggest an age-dependent role of CDKs. Together, we provide evidence that WJ-
MSCs modulate crucial cell fate pathways in an immature brain injury setting. We 
hypothesize that targeting these pathways impacts the regeneration capacity of a 
developing brain. Additional studies will dissect which specific pathways such as 
AKT/CDK/14-3-3 binding and factors such as LIF may produce beneficial effects. 
Furthermore, studies addressing the direct comparison of different cell transplants 
including adipose-derived stem cells and bone marrow mononuclear cells will 
determine whether the documented effects (Fig. 3) are WJ-MSCs specific as well.   
 
In conclusion, disease-specific and age-specific considerations are necessary when 
assessing therapeutics for immature infants. Additional studies identifying WJ-MSCs’ 
optimal formulation and preparation (live cells versus cell products), transplantation 
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routes (invasive versus non-invasive), and design (alone versus synergistic additives) 
need to be addressed prior to clinical translation. We hypothesize that WJ-MSCs may 
exert adaptive responses depending on the type of injury they are facing, making 
them prominent candidates for cell therapy in perinatal injuries. 
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Tables: 
 
Table 1: Gene expression profile of WJ-MSCs and differentiated neurospheres in 
culture.  
We examined gene expression using specific profiler PCR array. The table shows 
significantly expressed genes of WJ-MSCs compared to neurospheres derived from 
WJ-MSCs in culture. We used an arbitrary cutoff of more than twofold change and 
p<0.05. 
 
 
RefSeq Symbol Description 
2^-∆Ct 
Fold Upregulation or 
Downregulation 
  
WJ-MSCs 
Neuro-
spheres 
WJ-
MSCs/Neurospheres 
p 
value 
NM_001709 BDNF 
Brain-derived 
neurotrophic factor 
1.1E-02 5.0E-02 -4.72 0.0305 
NM_001882 CRHBP 
Corticotropin 
releasing hormone 
binding protein 
2.6E-05 3.9E-06 6.66 0.0046 
NM_002010 FGF9 
Fibroblast growth 
factor 9 (glia-
activating factor) 
9.2E-06 1.4E-04 -15.57 0.0355 
NM_004960 FUS Fused in sarcoma 3.8E-02 1.0E-01 -2.62 0.0367 
NM_005264 GFRA1 
GDNF family 
receptor alpha 1 
9.6E-04 1.7E-02 -17.56 0.0465 
NM_001496 GFRA3 
GDNF family 
receptor alpha 3 
3.0E-05 5.4E-06 5.58 0.0001 
NM_001540 HSPB1 
Heat shock 27kDa 
protein 1 
5.5E-01 1.5E+00 -2.80 0.0065 
NM_000565 IL6R 
Interleukin 6 
receptor 
4.7E-04 1.6E-03 -3.42 0.0034 
NM_002309 LIF 
Leukemia inhibitory 
factor  
2.2E-01 4.2E-02 5.36 0.0021 
NM_002507 NGFR 
Nerve growth factor 
receptor 
4.7E-04 4.7E-05 9.94 0.0035 
NM_002527 NTF3 Neurotrophin 3 1.1E-03 9.9E-03 -8.98 0.0001 
NM_000956 PTGER2 
Prostaglandin E 
receptor 2 (subtype 
EP2) 
1.9E-02 7.0E-03 2.67 0.0455 
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Figure Legends 
 
Figure 1. 
WJ-MSCs as a cell transplant 
A: WJ-MSCs show unaltered morphology and (B) express typical MSCs markers. C: 
WJ-MSCs transplantation in immature brain injury model. D: WJ-MSCs (arrow: HLA-
ABC positive cells) were detected in the brain cortex (cresyl violet staining) at P39. 
Scale bar represents 100µm. 
WJ-MSCs: Wharton Jelly derived mesenchymal stem/stromal cells.  
 
 
Figure 2. 
WJ-MSCs protect the immature brain 
A: Quantification of loco-motor behavior (A). Representative immunohistochemistry 
images of neuronal loss (B), myelin loss (C upper panel), and astroglial activation (D 
upper panel) in deep cortical sections of both hemispheres. Quantification of myelin 
loss (C lower panel), and astroglial activation (D lower panel). Data are presented 
as mean±SEM (n=19, two-tailed Student`s t-test). Scale bar, 50µm. *p<0.05; 
***p<0.001. 
NeuN (nuclear specific nuclear protein) marker for neurons; MBP (myelin basic 
protein) marker for myelin; GFAP (glial fibrillary acidic protein) marker for astrogliosis. 
 
Figure 3. 
WJ-MSCs modulate crucial cell fate pathways 
Proteins were extracted from frozen brain tissues (n=3 each group) and analyzed by 
Western blot. In upper panels representative western blots and in lower panels 
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quantification of cyclic AMP dependent protein kinase / calcium-dependent protein 
kinase (PKA/PKC) (A), cyclin-dependent kinase (CDK) (B), ataxia-telangiectasia-
mutated/ATM- and Rad3-related (ATM/ATR) substrates (C), Protein kinase B (Akt) 
(D), and 14-3-3 binding protein partners (E). F: Hypothesis: WJ-MSCs protect the 
immature brain and modulate cell fate signaling pathways G: Representative western 
blots (3 independent experiments) of leukemia inhibitory factor (LIF) identified in the 
gene array (Tab. 1) as one of the factors highly upregulated in WJ-MSCs. Protein 
levels are shown after normalization against beta-actin. Data are presented as mean
±SEM (two-tailed Student`s t-test). *p<0.05; **p<0.01; ***p<0.001 
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SUPPLEMENTARY INFORMATION 
Wharton`s jelly Mesenchymal Stem Cells protect the immature brain in rats by 
modulating cell fate 
 
Martin MUELLER, MD1,2; Byron OPPLIGER PhD1; Marianne JOERGER-MESSERLI, 
PhD1; Ursula REINHART1; Eytan BARNEA, MD3; Michael PAIDAS, MD2; Boris W, 
KRAMER, MD, PhD4, Daniel V. SURBEK, MD1; Andreina SCHOEBERLEIN, PhD1 
 
SUPPLEMENTARY METHODS 
 
Perioperative Care of the Animals 
Perioperative care was performed in accordance with Ethics Committee and 
Veterinary Department of the Canton of Berne, Switzerland guidelines. 
Acclimatization of animals to the laboratory environment was allowed prior to surgery. 
Aseptic rodent survival surgery guidelines were followed. We injected Buprenorphine 
(0.1 mg/kg body weight) subcutaneously (s.c.) 30 min prior incision. Carprofen was 
used for postoperative analgesia (5 mg/kg, s.c., starting 4-6 hours post-surgery, 
every 24 hours for 3 days). We used Isoflurane as an anesthetic (induction with 4% 
and maintenance with 1-1.5% in O2; 3l/min). Adequate depth of anesthesia was 
confirmed. After surgery, animals were placed back to the mother as soon as they 
were awake, able to right themselves and able to move about. We monitored several 
parameters including anesthetic depth (persistence), clinical signs and condition. We 
monitored the pups every hours for at least 6-8 hours post operation with special 
attention to breathing pattern and mobility, as well as signs of seepage or bleeding 
from the incision. When neonates have reached the age of interest, animals were 
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sacrificed by Natrium-Pentothal (100mg/kg body weight i.p.), cardiac perfusion and 
decapitation.  
Tissue Immunohistochemistry 
After deparaffinization of the slides, the target was retrieved in citrate buffer (10 mM; 
pH 6.0) in a pressure cooker for 15 minutes. Slides were washed in 0.1% Tween-
20/PBS and blocked in 10% goat serum/1% bovine albumin/PBS. WJ-MSCs were 
detected with a mouse anti-human HLA class I ABC antibody (EMR8-5, Abcam, 
Cambridge, UK) and the DakoCytomation EnVision+ System-HRP (K4006, DAKO, 
Glostrup, Denmark). Neurons were detected by a mouse monoclonal antibody 
specific for the neuronal nuclear antigen (NeuN, Merck Millipore, MAB377, 1:100). 
Myelin was detected by an antibody against MBP (myelin basic protein, mouse anti-
human monoclonal antibody, LifeSpan Biosciences LSBio, Seattle, WA, LS-B2231, 
1:100). Astrogliosis was detected with an antibody against GFAP (glial fibrillary acidic 
protein, mouse monoclonal anti-GFAP, Merck Millipore MAB360, 1:500 in DAKO 
Antibody diluent). Following first antibody incubation, slides were washed in 0.1% 
Tween-20/PBS (2x 5min) and incubated in endogenous peroxidase blocking solution 
at RT for 15 min. Peroxidase-labeled polymer (DAKO anti mouse or anti rabbit) was 
applied to the slides for 30 min at RT. Slides were washed in PBS (3x5 min), followed 
by the application of DAB+ chromogen in buffer substrate for 10-30 min, according to 
the manufacturer’s instructions (DAKO EnVision+ System-HRP (DAB), K4007). 
Slides were rinsed in ddH2O, counterstained in Cresyl violet (Nissl body staining for 
neuronal structure and gross brain morphology), dehydrated in a series of ethanol 
baths (95% >100%) and xylene, and mounted with Eukitt (Sigma-Aldrich, St. Louis, 
MO).  
Tissue Harvesting  
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The western blots using antibodies specific motifs were performed as we had 
described previously [1]. To dissect WJ-MSCs protective mechanisms in the brain 
tissue (n=3 each group), we induced brain injury as previously described [1,2]. Injury 
and Injury+WJ-MSCs groups received Lipopolysaccharides (LPS 0.1mg/kg BW, i.p.) 
at postnatal day 2 (P2). On the following day, left common carotid artery was double-
ligated using a stereomicroscope and animals were subjected to hypoxia (8% O2/ 
92% N2; 65 minutes). The Sham Group consisted of uninjured animals (0.9% NaCl 
instead of LPS i.p., exposure of carotid artery without ligation, no hypoxia and 
received no treatment. The Injury Group received no further treatment but ne needle 
was placed into the ventricle. The Injury+WJ-MSCs Group received a single cell graft 
transplantation into the lateral ventricle. We transplanted 250‘000 of WJ-MSCs into 
the ventricle at postnatal day 4 as published previously [3]. We harvested the brain 
tissue at P11 and evaluated specific motif. antibodies as previously performed [2].  
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